Physician profile
Meredith D Stempel
NPI 1992800700
$11,465.98
in general payments reported to CMS, 2019-2025
34 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $706 · 2021: $2,005 · 2022: $1,815 · 2023: $2,756 · 2024: $1,631 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,658 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,658.19 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,451.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,383.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,340.06 | 2019-2025 | Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $1,031.07 | 2020-2025 | Nexletol, Nexlizet |
| Abbvie INC. | $924.12 | 2020-2025 | Creon, Linzess, Viberzi |
| Aimmune Therapeutics, INC. | $510.23 | 2024-2025 | Zenpep, Vowst |
| Medtronic, INC. | $484.00 | 2022-2023 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $470.45 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $445.42 | 2019-2022 | |
| Pfizer INC. | $364.33 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $356.71 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $324.17 | 2021-2023 | |
| Boston Scientific Corporation | $309.51 | 2022-2023 | Infinion 16 |
| Lilly USA, LLC | $303.26 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $283.93 | 2019-2023 | Otezla, Repatha |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $249.48 | 2024 | Voquezna |
| Mylan Specialty L.P. | $248.43 | 2021-2023 | Yupelri |
| Amarin Pharma, INC. | $132.56 | 2020 | |
| Mannkind Corporation | $125.00 | 2019 | |
| Kyowa Kirin, INC. | $124.80 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.19 | 2022 | |
| Merck Sharp & Dohme LLC | $95.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $74.11 | 2022-2023 | Quviviq |
| Abbott Laboratories | $48.78 | 2021-2022 | |
| Exact Sciences Corporation | $46.49 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $29.90 | 2021-2022 | |
| Biogen, INC. | $17.10 | 2022 | |
| Almatica Pharma LLC | $16.87 | 2025 | Loreev Xr |
| Baxter Healthcare | $16.81 | 2025 | Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $16.30 | 2023 | |
| Philips North America LLC | $16.22 | 2023 | |
| Sumitomo Pharma America, INC. | $15.81 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Stempel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.